Literature DB >> 19121257

Cannabinoid hyperemesis relieved by compulsive bathing.

Yoon Hee Chang1, Donna M Windish.   

Abstract

Cannabinoid hyperemesis is a clinical syndrome characterized by repeated vomiting and associated learned compulsive hot water bathing behavior due to long-term marijuana use. Research has identified type 1 cannabinoid receptors in the intestinal nerve plexus that have an inhibitory effect on gastrointestinal motility. This inhibitory effect may lead to hyperemesis in marijuana users. The thermoregulatory role of endocannabinoids may be responsible for the patient's need to take hot showers. We report 2 cases of cannabinoid hyperemesis that demonstrate this unusual adverse effect of marijuana use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19121257      PMCID: PMC2664574          DOI: 10.1016/S0025-6196(11)60811-2

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

Review 1.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

Authors:  Nissar A Darmani
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

3.  Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study.

Authors:  R W McCallum; I Soykan; K R Sridhar; D A Ricci; R C Lange; M W Plankey
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

4.  Cortical, thalamic, and hypothalamic responses to cooling and warming the skin in awake humans: a positron-emission tomography study.

Authors:  Gary F Egan; John Johnson; Michael Farrell; Robin McAllen; Frank Zamarripa; Michael J McKinley; Jack Lancaster; Derek Denton; Peter T Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

5.  Toxicity with intravenous injection of crude marijuana extract.

Authors:  N D Vaziri; R Thomas; M Sterling; K Seiff; M V Pahl; J Davila; A Wilson
Journal:  Clin Toxicol       Date:  1981-03       Impact factor: 4.467

6.  Cannabis use disorders in the USA: prevalence, correlates and co-morbidity.

Authors:  Frederick S Stinson; W June Ruan; Roger Pickering; Bridget F Grant
Journal:  Psychol Med       Date:  2006-07-20       Impact factor: 7.723

7.  The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets.

Authors:  I I Simoneau; M S Hamza; H P Mata; E M Siegel; T W Vanderah; F Porreca; A Makriyannis; T P Malan
Journal:  Anesthesiology       Date:  2001-05       Impact factor: 7.892

8.  Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.

Authors:  J H Allen; G M de Moore; R Heddle; J C Twartz
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002.

Authors:  Wilson M Compton; Bridget F Grant; James D Colliver; Meyer D Glantz; Frederick S Stinson
Journal:  JAMA       Date:  2004-05-05       Impact factor: 56.272

Review 10.  Metoclopramide: pharmacology and clinical application.

Authors:  R Albibi; R W McCallum
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

View more
  33 in total

1.  Cannabinoid hyperemesis: a case series of 98 patients.

Authors:  Douglas A Simonetto; Amy S Oxentenko; Margot L Herman; Jason H Szostek
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Cannabinoid hyperemesis.

Authors:  Kim Wild; Hugh Wilson
Journal:  BMJ Case Rep       Date:  2010-09-07

3.  Confirming the diagnosis of cannabinoid hyperemesis.

Authors:  Vikram Budhraja
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

4.  Cannabinoid hyperemesis syndrome.

Authors:  Jose M Roca-Pallín; Hugo López-Pelayo; Gisela Sugranyes; Maria M Balcells-Oliveró
Journal:  CNS Neurosci Ther       Date:  2013-12       Impact factor: 5.243

5.  Clinical pearls in gastroenterology.

Authors:  Amy S Oxentenko; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2009-10       Impact factor: 7.616

6.  Case of cannabinoid hyperemesis syndrome with long-term follow-up.

Authors:  Jae Myung Cha; Richard A Kozarek; Otto S Lin
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

7.  Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers.

Authors:  Jennifer H Martin; Nicholas J Talley
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

8.  Some like it hot: erythema ab igne due to cannabinoid hyperemesis.

Authors:  Ryan R Kraemer; Ricardo M La Hoz; James H Willig
Journal:  J Gen Intern Med       Date:  2013-04-24       Impact factor: 5.128

9.  Running Out of Options: Rhabdomyolysis Associated with Cannabis Hyperemesis Syndrome.

Authors:  Bernard E Trappey; Andrew P J Olson
Journal:  J Gen Intern Med       Date:  2017-06-29       Impact factor: 5.128

10.  Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse.

Authors:  Siva P Sontineni; Sanjay Chaudhary; Vijaya Sontineni; Stephen J Lanspa
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.